Neurotoxic effects of exogenous recombinant tissue-type plasminogen activator on the normal rat brain

Journal of Neurotrauma

Volumn 24, Issue 4, 2007, Pages 745-752

  Goto, Hisaharu ^a   Fujisawa, Hirosuke ^a   Oka, Fumiaki ^a   Nomura, Sadahiro ^a   Kajiwara, Koji ^a   Kato, Shoichi ^b   Fujii, Masami ^a   Maekawa, Tsuyoshi ^a   Suzuki, Michiyasu ^a  

^a YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

Basal lamina; Blood brain barrier; Microdialysis; Neurotoxicity; Tissue type plasminogen activator

Indexed keywords

ALTEPLASE; ANTIBODY; EVANS BLUE; LAMININ; COLORING AGENT; RECOMBINANT PROTEIN; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASEMENT MEMBRANE; BLOOD BRAIN BARRIER; BRAIN EDEMA; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG MEGADOSE; EXTRAVASATION; FIBRINOLYTIC THERAPY; HISTOLOGY; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MICRODIALYSIS; NERVE CELL NECROSIS; NEUROTOXICITY; NONHUMAN; QUANTITATIVE ANALYSIS; RAT; WISTAR RAT; ANIMAL; BLOOD GAS ANALYSIS; BLOOD PRESSURE; BODY TEMPERATURE; BRAIN; CELL DEATH; EXTRACELLULAR SPACE; MALE; METABOLISM; PATHOLOGY; PH; PHYSIOLOGY; TOXICITY AND INTOXICATION;

ANIMALS; BLOOD GAS ANALYSIS; BLOOD PRESSURE; BLOOD-BRAIN BARRIER; BODY TEMPERATURE; BRAIN; BRAIN EDEMA; CELL DEATH; COLORING AGENTS; EVANS BLUE; EXTRACELLULAR SPACE; HYDROGEN-ION CONCENTRATION; IMMUNOHISTOCHEMISTRY; LAMININ; MALE; NEUROTOXICITY SYNDROMES; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 34249845166     PISSN: 08977151     EISSN: None     Source Type: Journal    
DOI: 10.1089/neu.2006.0183     Document Type: Article

References (31)

1. ANDERSEN, M., OVERGAARD, K., MEDEN, P., BOYSEN, G., and CHOI, S.C. (1999). Effects of citicoline combined with thrombolytic therapy in a rat embolic stroke model. Stroke 30, 1464-1471.
2. ASAHI, M., WANG, X., MORI, T., et al. (2001). Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J. Neurosci. 21, 7724-7732.
3. BENCHENANE, K., BEREZOWSKI, V., ALI, C., et al. (2005). Tissue-type plasminogen activator crosses the intact blood-brain barrier by low-density lipoprotein receptor-related protein-mediated transcytosis. Circulation 111, 2241-2249.
4. BENVENISTE, H. (1989). Brain microdialysis. J. Neurochem. 52, 1667-1679.
5. CHEN, Z.L., and STRICKLAND, S. (1997). Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. Cell 91, 917-925.
6. HAMANN, G.F., LIEBETRAU, M., MARTENS, H., et al. (2002). Microvascular basal lamina injury after experimental focal cerebral ischemia and reperfusion in the rat. J. Cereb. Blood Flow Metab. 22, 526-533.
7. HAMANN, G.F., SCHROCK, H., BURGGRAF, D., WUNDERLICH, N., LIEBETRAU, M., and KUSCHINSKY, W. (2003). Microvascular Basal lamina damage after embolic stroke in the rat: relationship to cerebral blood flow. J. Cereb. Blood Flow Metab. 23, 1293-1297.
8. KAUR, J., ZHAO, Z., KLEIN, G.M., LO, E.H., and BUCHAN, A.M. (2004). The neurotoxicity of tissue plasminogen acti-vator? J. Cereb. Blood Flow Metab. 9, 945-963.
9. KILIC, E., BAHR, M., and HERMANN, D.M. (2001). Effects of recombinant tissue plasminogen activator after intraluminal thread occlusion in mice: role of hemodynamic alterations. Stroke 32, 2641-2647.
10. KLEIN, G.M., LI, H., SUN, P., and BUCHAN, A.M. (1999). Tissue plasminogen activator does not increase neuronal damage in rat models of global and focal ischemia. Neurology 52, 1381-1384.
11. KRYSTOSEK, A., and SEEDS, N. (1981). Plasminogen activator secretion by granule neurons of developing cerebellum. Proc. Natl. Acad. Sci. USA 78, 7810-7814.
12. KRYSTOSEK, A., and SEEDS, N. (2001). Plasminogen activator release at the neuronal growth cone. Science 213, 1532-1534.
13. LIJNEN, H.R., van HOEF, B., BEELEN, V., et al. (1994). Characterization of the murine plasma fibrinolytic system. Eur. J. Biochem. 224, 863-871.
14. MENG, W., WANG, X., ASAHI, M., et al. (1999). Effects of tissue type plasminogen activator in embolic versus mechanical models of focal cerebral ischemia in rats. J. Cereb. Blood Flow Metab. 19, 1316-1321.
15. NAGAI, N., YAMAMOTO, S., TSUBOI, T., et al. (2001). Tissue type plasminogen activator is involved in the process of neuronal death by oxygen-glucose deprivation. J. Cereb. Blood Flow Metab. 21, 631-634.
16. NICHOLLS, D., and ATTWELL, D. (1990). The release and uptake of excitatory amino acids. Trends Pharmacol. Sci. 11, 462-468.
17. NICOLE, O., DOCAGNE, F., ALI, C., et al. (2001). The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat. Med. 7, 59-64.
18. NINDS (NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE). (1995). Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med. 333, 1581-1587.
19. PLANAS, A.M., JUSTICIA, C., SOLE, S., et al. (2002). Certain forms of matrix metalloproteinase-9 accumulate in the extracellular space after microdialysis probe implantation and middle cerebral artery occlusion/ reperfusion. J. Cereb. Blood Flow Metab. 22, 918-925.
20. REDDROP, C., MOLDRICH, R.X., BEART, P.M., et al. (2005). Vampire bat salivary plasminogen activator (desmoteplase) inhibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury. Stroke 36, 1241-1246.
21. ROMANIC, A.M., and MADRI, J.A. (1994). Extracellular matrix-degrading proteinases in the nervous system. Brain Pathol. 4, 145-156.
22. SIAO, C.J., and TSIRKA, S.E. (2002a). Extracellular proteases and neuronal cell death. Cell Mol. Biol. 48, 151-161.
23. SIAO, C.J., and TSIRKA, S.E. (2002b). Tissue type activator mediates microglial activation via its finger domain through Annexin II. J. Neurosci. 22, 3352-3358.
24. SIESJO, B.K. (1992). Pathophysiology and treatment of focal cerebral ischemia. Part II: Mechanisms of damage and treatment. J. Neurosurg. 77, 337-354.
25. TOSSMAN, U., and UNGERSTEDT, U. (1986). Microdialysis in the study of extracellular levels of amino acids in the brain. Acta Physiol. Scand. 128, 9-14.
26. TSIRKA, S.E., ROGOVE, A.D., BUGGE, T.H., DEGEN, J.L., and STRICKLAND, S. (1997). An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus. J. Neurosci. 17, 543-552.
27. TSUJI, K., AOKI, T., TEJIMA, E., et al. (2005). Tissue plasminogen activator promotes matrix metaIloproteinase-9 upregulation after focal cerebral ischemia. Stroke 36, 1954-1959.
28. VOSKO, M.R., BUSCH, E., BURGGRAF, D., BULTERMEIER, G., and HAMANN, G.F. (2003). Microvascular basal lamina damage in thromboembolic stroke in a rat model. Neurosci. Lett. 353, 217-220.
29. WANG, X., TSUJI, K., LEE, S.R., et al. (2004). Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke 35, 2726-2730.
30. YAMAGUCHI, T., MORI, E., MINEMATSU, K., et al. (2006). Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke 37, 1810-1815.
31. YEPES, M., SANDKVIST, M., MOORE, E.G., BUGGE, T.H., STRICKLAND, D.K., and LAWRENCE, D.A. (2003). Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J. Clin. Invest. 112, 1533-1540.